Sanofi To Test Arthritis Drug Kevzara For Coronavirus
'Scientific Rationale' Behind Regeneron-partnered IL-6 Inhibitor
The French giant is already working on a vaccine to combat COVID-19 and is now evaluating whether its rheumatoid arthritis drug Kevzara could treat pulmonary complications related to the coronavirus.
You may also be interested in...
US FDA/NIH smartphone app is intended to allow clinicians and others to talk about potential treatments for infectious diseases, but so far COVID-19-related activity has been limited.
A string of actions to ensure medicines security and prioritize bulk drug project clearances are underway in India as the country enters a critical phase in its efforts to contain coronavirus cases.
The Phase II/III trial will begin enrolling patients in the US immediately, with Regeneron taking the lead in US development and Sanofi leading ex-US trials.